PTGX
Price
$140.97
Change
-$1.47 (-1.03%)
Updated
Sep 29 closing price
Capitalization
9.22B
36 days until earnings call
Intraday BUY SELL Signals
QNRX
Price
$4.86
Change
-$0.02 (-0.41%)
Updated
Sep 30, 10:41 AM (EDT)
Capitalization
10.56M
Intraday BUY SELL Signals
Interact to see
Advertisement

PTGX vs QNRX

PTGX vs QNRX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
PTGX vs. QNRX commentary
Sep 30, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PTGX is a StrongBuy and QNRX is a Buy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
PTGX vs QNRX: Fundamental Ratings
PTGX
QNRX
OUTLOOK RATING
1..100
7997
VALUATION
overvalued / fair valued / undervalued
1..100
92
Overvalued
26
Undervalued
PROFIT vs RISK RATING
1..100
17100
SMR RATING
1..100
59100
PRICE GROWTH RATING
1..100
3761
P/E GROWTH RATING
1..100
1211
SEASONALITY SCORE
1..100
1585

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

QNRX's Valuation (26) in the Biotechnology industry is significantly better than the same rating for PTGX (92). This means that QNRX’s stock grew significantly faster than PTGX’s over the last 12 months.

PTGX's Profit vs Risk Rating (17) in the Biotechnology industry is significantly better than the same rating for QNRX (100). This means that PTGX’s stock grew significantly faster than QNRX’s over the last 12 months.

PTGX's SMR Rating (59) in the Biotechnology industry is somewhat better than the same rating for QNRX (100). This means that PTGX’s stock grew somewhat faster than QNRX’s over the last 12 months.

PTGX's Price Growth Rating (37) in the Biotechnology industry is in the same range as QNRX (61). This means that PTGX’s stock grew similarly to QNRX’s over the last 12 months.

QNRX's P/E Growth Rating (11) in the Biotechnology industry is in the same range as PTGX (12). This means that QNRX’s stock grew similarly to PTGX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PTGXQNRX
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
89%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 1 day ago
81%
Momentum
ODDS (%)
Bearish Trend 1 day ago
68%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 7 days ago
76%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 13 days ago
83%
Declines
ODDS (%)
Bearish Trend 7 days ago
75%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
88%
Aroon
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
90%
COMPARISON
Comparison
Sep 30, 2026
Stock price -- (PTGX: $140.97 vs. QNRX: $4.88)
Brand notoriety: PTGX and QNRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PTGX: 89% vs. QNRX: 18%
Market capitalization -- PTGX: $9.22B vs. QNRX: $10.56M
PTGX [@Biotechnology] is valued at $9.22B. QNRX’s [@Biotechnology] market capitalization is $10.56M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PTGX’s FA Score shows that 2 FA rating(s) are green while QNRX’s FA Score has 2 green FA rating(s).

  • PTGX’s FA Score: 2 green, 3 red.
  • QNRX’s FA Score: 2 green, 3 red.
According to our system of comparison, PTGX is a better buy in the long-term than QNRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PTGX’s TA Score shows that 3 TA indicator(s) are bullish while QNRX’s TA Score has 5 bullish TA indicator(s).

  • PTGX’s TA Score: 3 bullish, 6 bearish.
  • QNRX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, QNRX is a better buy in the short-term than PTGX.

Price Growth

PTGX (@Biotechnology) experienced а -2.83% price change this week, while QNRX (@Biotechnology) price change was -30.39% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.40%. For the same industry, the average monthly price growth was -11.74%, and the average quarterly price growth was +0.75%.

Reported Earning Dates

PTGX is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (-6.40% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
PTGX
Daily Signal:
Gain/Loss:
QNRX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ATOM4.230.08
+1.93%
Atomera
PCG12.180.23
+1.92%
PG&E Corp
HIVE3.01-0.03
-0.99%
HIVE Digital Technologies Ltd
LZMH1.11-0.04
-3.48%
LZ Technology Holdings Limited
FLY22.86-1.25
-5.18%
Firefly Aerospace Inc.